United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $462.94, for a total value of $1,851,760.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $60,182.20. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

Shares of UTHR stock opened at $476.59 on Wednesday. The business’s fifty day moving average price is $435.39 and its 200 day moving average price is $352.54. The firm has a market capitalization of $20.52 billion, a PE ratio of 18.06, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $485.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter last year, the company earned $6.39 earnings per share. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. UBS Group lifted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Wednesday. Bank of America lifted their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Finally, Cantor Fitzgerald raised their price target on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $503.90.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the stock. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the 3rd quarter worth about $317,617,000. Norges Bank purchased a new position in United Therapeutics in the 2nd quarter valued at about $136,453,000. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of United Therapeutics during the first quarter worth about $83,533,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.